ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Allergan (AGN)
DateTimeHeadline
06/30/201516:31:06Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:30:42Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:30:15Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:28:04Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:27:12Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:24:34Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:22:15Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:18:41Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:15:42Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201516:14:23Amended Statement of Changes in Beneficial Ownership (4/a)
06/30/201514:19:29Towers Watson: Lower Taxes Not Main Driver of Willis Deal
06/29/201516:05:00Allergan to Host Second Quarter 2015 Earnings Conference Call...
06/26/201516:09:34Annual Report of Employee Stock Plans (11-k)
06/25/201509:20:03Eli Lilly Wins Alimta Patent Case in U.K.
06/25/201509:08:25Eli Lilly Wins Alimta Patent Case in U.K.
06/19/201512:35:57Stocks: Following China's Correction, Will Biotechnology Be Next?
06/19/201510:30:12Kythera Prices Double-Chin Injection
06/18/201510:09:00SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders...
06/17/201516:55:00Robbins Arroyo LLP: Acquisition of KYTHERA Biopharmaceuticals...
06/17/201511:22:00KYTHERA BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky...

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad